Omeros® Corporation is a valued OOSS Resource Partner. Resource Partners provide products and services that may be of interest to OOSS members. These partners support OOSS through financial and in-kind contributions. Learn more about the OOSS Partner program.
Omidria® changes the approach to intraoperative miosis and postoperative ocular pain.
Omeros® is the manufacturer of OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3%, the first and only FDA-approved product of its kind for cataract surgery, delivering both miosis prevention and postoperative pain reduction.
To learn more about OMIDRIA® CLICK HERE.
CLICK HERE for full prescribing information for OMIDRIA®.
Now with the comprehensive reimbursement program OMIDRIAssure™, you can provide the benefits of OMIDRIA without worrying about coverage and reimbursement. Because all cataract surgery patients deserve OMIDRIA® regardless of their insurance coverage, OMIDRIAssure™ offers the following services to ophthalmic surgical facilities:
- Live Assistance Information Hotline.
- “Equal Access” Patient Assistance Program for government-insured and uninsured patients.
- “We Pay the Difference” Commercial Reimbursement Program for commercially insured patients.
To learn more about OMIDRIAAssure™, CLICK HERE.
Omeros®, a Seattle-based biopharmaceutical company, develops and produces small-molecule and protein therapeutics designed to improve clinical outcomes in surgical and medical procedures. To learn more about Omeros®, CLICK HERE.
IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE: OMIDRIA® is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. OMIDRIA® must be added to irrigation solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA® with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Use of OMIDRIA in children has not been established. Please see the Full Prescribing Information for OMIDRIA®. You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.